Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Lithium treatment may prevent suicide-related events in patients with bipolar disorder

14 Aug 2017

The use of lithium treatment appears to be effective in patients with bipolar disorder with suspected suicidal intentions, according to a recent study. However, risk for suicide is only one of the many considerations when providing clinical care.

Researchers utilized within-individual designs in a register-based longitudinal cohort to examine the associations of lithium and valproate, the most common alternative to lithium, with the risk of suicide-related events and potential differences between the two drugs. They followed 51,535 individuals with bipolar disorder from 2005 to 2013 through linkage of several Swedish national registers.

Hazard ratios (HRs) of suicide-related events during treated vs untreated periods were estimated using stratified Cox regression. The population attributable fractions were also estimated to evaluate the public health impact for patients with bipolar disorder.

A total of 10,648 suicide-related events occurred during follow-up. Lithium treatment significantly reduced the incidence rate by 14 percent (HR, 0.86; 95 percent CI, 0.78 to 0.95), but valproate treatment did not (HR, 1.02; 0.89 to 1.15).

There was a statistically significant difference in HRs of suicide-related events between lithium and valproate. Based on estimates of the population attributable fraction, administering lithium during the entire follow-up could have prevented 12 percent (4 to 20 percent) of suicide-related events.

“Conclusions regarding lithium’s antisuicidal effect for bipolar disorder have been limited due to nonrepresentative subjects and potential confounding factors, including varying severity of illness,” according to researchers. “Findings regarding the effect of valproate … are inconsistent for suicidal behaviour.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.